Kidney treatment developer Tricida raises $30M in Series B

Biotech firm Tricida raised $30 million in Series B funding on Wednesday to take its chronic kidney disease treatment into clinical trials. Existing investor OrbiMed led the round with participation by Sibling Capital Ventures and Limulus Venture Partners. The company has raised $44.5 million to date. CEO Gerrit Klaerner heads up the South San Francisco-based company, which was founded in 2013. Klaerner co-founded Ilypsa in 2003 to develop renal care pharmaceutical products, selling the company…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news